Genetically engineered mice as experimental tools to dissect the critical events in breast cancer

Advances in Cancer Research

Volumn 121, Issue , 2014, Pages 331-382

  Menezes, Mitchell E ^a   Das, Swadesh K ^a   Emdad, Luni ^a,b   Windle, Jolene J ^a,b   Wang, Xiang Yang ^a,b   Sarkar, Devanand ^a,b   Fisher, Paul B ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Breast cancer; Genetically engineered mouse (GEM) models; Transgenic animals

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; POLYOMA VIRUS MIDDLE T ANTIGEN; PROTEIN P53; SIMIAN VIRUS 40 T ANTIGEN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS MIDDLE T ANTIGEN; VIRUS T ANTIGEN; WNT PROTEIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST DEVELOPMENT; BREAST METASTASIS; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; DISSECTION; EXPERIMENTAL MOUSE; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; IMAGING; KNOCKOUT MOUSE; MAMMARY GLAND; NONHUMAN; ONCOGENE; ONCOGENE C MYC; ONCOGENE H RAS; POLYOMA VIRUS; PRIORITY JOURNAL; SIMIAN VIRUS 40; SUPPRESSOR GENE; TRANSGENIC ANIMAL; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; DISEASE MODEL; FEMALE; GENETICS; MOUSE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; UDDER;

ANIMALS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MICE; MICE, TRANSGENIC; SIGNAL TRANSDUCTION;

EID: 84990010219     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800249-0.00008-1     Document Type: Chapter

References (165)

1. Abrams T.J., Murray L.J., Pesenti E., Holway V.W., Colombo T., Lee L.B., et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Molecular Cancer Therapeutics 2003, 2:1011-1021.
2. Ahmed F., Wyckoff J., Lin E.Y., Wang W., Wang Y., Hennighausen L., et al. GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice. Cancer Research 2002, 62:7166-7169.
3. Ahuja D., Saenz-Robles M.T., Pipas J.M. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005, 24:7729-7745.
4. Amundadottir L.T., Johnson M.D., Merlino G., Smith G.H., Dickson R.B. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis. Cell Growth & Differentiation: The molecular biology journal of the American Association for Cancer Research 1995, 6:737-748.
5. Amundadottir L.T., Nass S.J., Berchem G.J., Johnson M.D., Dickson R.B. Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: Coordinated stimulation of growth and suppression of apoptosis. Oncogene 1996, 13:757-765.
6. Andrechek E.R., Hardy W.R., Siegel P.M., Rudnicki M.A., Cardiff R.D., Muller W.J. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:3444-3449.
7. Andres A.C., Schonenberger C.A., Groner B., Hennighausen L., LeMeur M., Gerlinger P. Ha-ras oncogene expression directed by a milk protein gene promoter: Tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:1299-1303.
8. Andres A.C., van der Valk M.A., Schonenberger C.A., Fluckiger F., LeMeur M., Gerlinger P., et al. Ha-ras and c-myc oncogene expression interferes with morphological and functional differentiation of mammary epithelial cells in single and double transgenic mice. Genes & Development 1988, 2:1486-1495.
9. Asch B.B. Tumor viruses and endogenous retrotransposons in mammary tumorigenesis. Journal of Mammary Gland Biology and Neoplasia 1996, 1:49-60.
10. Barnes D.M., Gillett C.E. Cyclin D1 in breast cancer. Breast Cancer Research and Treatment 1998, 52:1-15.
11. Barrington R.E., Subler M.A., Rands E., Omer C.A., Miller P.J., Hundley J.E., et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Molecular and Cellular Biology 1998, 18:85-92.
12. Bartkova J., Lukas J., Muller H., Lutzhoft D., Strauss M., Bartek J. Cyclin D1 protein expression and function in human breast cancer. International Journal of Cancer 1994, 57:353-361.
13. The mammary gland as an experimental model. Cold Spring Harbor perspectives in biology 2011, Cold Spring Harbor Laboratory Press, Online ISSN: 1943-0264. M.J. Bissell, K. Polyak, J.M. Rosen (Eds.).
14. Blackburn A.C., Jerry D.J. Knockout and transgenic mice of Trp53: What have we learned about p53 in breast cancer?. Breast Cancer Research: BCR 2002, 4:101-111.
15. Blackshear P.E. Genetically engineered rodent models of mammary gland carcinogenesis: An overview. Toxicologic Pathology 2001, 29:105-116.
16. Bocchinfuso W.P., Hively W.P., Couse J.F., Varmus H.E., Korach K.S. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Research 1999, 59:1869-1876.
17. Borowsky A.D. Genetically engineering a mouse. Comparative Medicine 2003, 53:249-250.
18. Borowsky A.D. Choosing a mouse model: Experimental biology in context - the utility and limitations of mouse models of breast cancer. Cold Spring Harbor Perspectives in Biology 2011, 3:a009670.
19. Bos J.L. ras oncogenes in human cancer: A review. Cancer Research 1989, 49:4682-4689.
20. Bouchard L., Lamarre L., Tremblay P.J., Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 1989, 57:931-936.
21. Bowe D.B., Kenney N.J., Adereth Y., Maroulakou I.G. Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E. Oncogene 2002, 21:291-298.
22. Boxer R.B., Jang J.W., Sintasath L., Chodosh L.A. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004, 6:577-586.
23. Brandt R., Eisenbrandt R., Leenders F., Zschiesche W., Binas B., Juergensen C., et al. Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 2000, 19:2129-2137.
24. Brinster R.L., Chen H.Y., Trumbauer M., Senear A.W., Warren R., Palmiter R.D. Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs. Cell 1981, 27:223-231.
25. Britt K., Ashworth A., Smalley M. Pregnancy and the risk of breast cancer. Endocrine-Related Cancer 2007, 14:907-933.
26. Buckley M.F., Sweeney K.J., Hamilton J.A., Sini R.L., Manning D.L., Nicholson R.I., et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993, 8:2127-2133.
27. Caligiuri I., Rizzolio F., Boffo S., Giordano A., Toffoli G. Critical choices for modeling breast cancer in transgenic mouse models. Journal of Cellular Physiology 2012, 227:2988-2991.
28. Cardiff R.D. Mouse models of human breast cancer. Comparative Medicine 2003, 53:250-253.
29. Cardiff R.D., Anver M.R., Gusterson B.A., Hennighausen L., Jensen R.A., Merino M.J., et al. The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting. Oncogene 2000, 19:968-988.
30. Cardiff R.D., Kinney N. Mouse mammary tumor biology: A short history. Advances in Cancer Research 2007, 98:53-116.
31. Cardiff R.D., Wellings S.R. The comparative pathology of human and mouse mammary glands. Journal of Mammary Gland Biology and Neoplasia 1999, 4:105-122.
32. Casey G. The BRCA1 and BRCA2 breast cancer genes. Current Opinion in Oncology 1997, 9:88-93.
33. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nature Reviews. Cancer 2002, 2:563-572.
34. Cho A., Haruyama N., Kulkarni A.B. Generation of transgenic mice. Current Protocols in Cell Biology 2009, Chapter 19, Unit 19 11.
35. Condeelis J., Weissleder R. In vivo imaging in cancer. Cold Spring Harbor Perspectives in Biology 2010, 2:a003848.
36. Conti L., Lanzardo S., Iezzi M., Montone M., Bolli E., Brioschi C., et al. Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding alphav beta3 integrins. Contrast Media & Molecular Imaging 2013, 8:350-360.
37. Corsino P.E., Davis B.J., Norgaard P.H., Parker N.N., Law M., Dunn W., et al. Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component. Neoplasia 2008, 10:1240-1252.
38. DeBortoli M.E., Abou-Issa H., Haley B.E., Cho-Chung Y.S. Amplified expression of p21 ras protein in hormone-dependent mammary carcinomas of humans and rodents. Biochemical and Biophysical Research Communications 1985, 127:699-706.
39. Deming S.L., Nass S.J., Dickson R.B., Trock B.J. C-myc amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance. British Journal of Cancer 2000, 83:1688-1695.
40. Deng C.X., Scott F. Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene 2000, 19:1059-1064.
41. Dilworth S.M. Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nature Reviews. Cancer 2002, 2:951-956.
42. Dimri G., Band H., Band V. Mammary epithelial cell transformation: Insights from cell culture and mouse models. Breast Cancer Research: BCR 2005, 7:171-179.
43. Donehower L.A., Godley L.A., Aldaz C.M., Pyle R., Shi Y.P., Pinkel D., et al. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes & Development 1995, 9:882-895.
44. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Butel J.S., et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221.
45. Fantl V., Smith R., Brookes S., Dickson C., Peters G. Chromosome 11q13 abnormalities in human breast cancer. Cancer Surveys 1993, 18:77-94.
46. Fantl V., Stamp G., Andrews A., Rosewell I., Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes & Development 1995, 9:2364-2372.
47. Fantozzi A., Christofori G. Mouse models of breast cancer metastasis. Breast Cancer Research 2006, 8:212.
48. Folkman J. The role of angiogenesis in tumor growth. Seminars in Cancer Biology 1992, 3:65-71.
49. Friedel R.H., Wurst W., Wefers B., Kuhn R. Generating conditional knockout mice. Methods in Molecular Biology 2011, 693:205-231.
50. Fu M., Wang C., Li Z., Sakamaki T., Pestell R.G. Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology 2004, 145:5439-5447.
51. Galie M., D'Onofrio M., Calderan L., Nicolato E., Amici A., Crescimanno C., et al. In vivo mapping of spontaneous mammary tumors in transgenic mice using MRI and ultrasonography. Journal of Magnetic Resonance Imaging 2004, 19:570-579.
52. Gillett C., Fantl V., Smith R., Fisher C., Bartek J., Dickson C., et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Research 1994, 54:1812-1817.
53. Gillett C., Smith P., Gregory W., Richards M., Millis R., Peters G., et al. Cyclin D1 and prognosis in human breast cancer. International Journal of Cancer 1996, 69:92-99.
54. Gowen L.C., Johnson B.L., Latour A.M., Sulik K.K., Koller B.H. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nature Genetics 1996, 12:191-194.
55. Green J.E., Shibata M.A., Yoshidome K., Liu M.L., Jorcyk C., Anver M.R., et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: Ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 2000, 19:1020-1027.
56. Grum-Schwensen B., Klingelhofer J., Grigorian M., Almholt K., Nielsen B.S., Lukanidin E., et al. Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors. Cancer Research 2010, 70:936-947.
57. Gusterson B.A., Stein T. Human breast development. Seminars in Cell & Developmental Biology 2012, 23:567-573.
58. Guy C.T., Cardiff R.D., Muller W.J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Molecular and Cellular Biology 1992, 12:954-961.
59. Guy C.T., Cardiff R.D., Muller W.J. Activated neu induces rapid tumor progression. The Journal of Biological Chemistry 1996, 271:7673-7678.
60. Guy C.T., Muthuswamy S.K., Cardiff R.D., Soriano P., Muller W.J. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes & Development 1994, 8:23-32.
61. Guy C.T., Webster M.A., Schaller M., Parsons T.J., Cardiff R.D., Muller W.J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:10578-10582.
62. Hakem R., de la Pompa J.L., Sirard C., Mo R., Woo M., Hakem A., et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996, 85:1009-1023.
63. Hallett M.A., Teng B., Hasegawa H., Schwab L.P., Seagroves T.N., Pourmotabbed T. Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of breast cancer. Breast Cancer Research: BCR 2013, 15:R12.
64. Halter S.A., Dempsey P., Matsui Y., Stokes M.K., Graves-Deal R., Hogan B.L., et al. Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations. The American Journal of Pathology 1992, 140:1131-1146.
65. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
66. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
67. Hand P.H., Thor A., Wunderlich D., Muraro R., Caruso A., Schlom J. Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. Proceedings of the National Academy of Sciences of the United States of America 1984, 81:5227-5231.
68. Hens J.R., Wysolmerski J.J. Key stages of mammary gland development: Molecular mechanisms involved in the formation of the embryonic mammary gland. Breast Cancer Research: BCR 2005, 7:220-224.
69. Hill A.D., Doyle J.M., McDermott E.W., O'Higgins N.J. Hereditary breast cancer. The British Journal of Surgery 1997, 84:1334-1339.
70. Transgenic mouse methods and protocols. Methods in molecular biology 2011, Vol. 693. 2nd ed. M.H. Hofker, J. van Deursen (Eds.).
71. Hosokawa Y., Papanikolaou A., Cardiff R.D., Yoshimoto K., Bernstein M., Wang T.C., et al. In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53. Transgenic Research 2001, 10:471-478.
72. Howe L.R., Subbaramaiah K., Patel J., Masferrer J.L., Deora A., Hudis C., et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Research 2002, 62:5405-5407.
73. Hughes E.D., Saunders T.L. Gene targeting in embryonic stem cells. Advanced protocols for animal transgenesis: An ISTT manual 2011, Springer Berlin Heidelberg, Berlin. S. Pease, T.L. Saunders (Eds.).
74. Hundley J.E., Koester S.K., Troyer D.A., Hilsenbeck S.G., Barrington R.E., Windle J.J. Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors. Cancer Research 1997, 57:600-603.
75. Hundley J.E., Koester S.K., Troyer D.A., Hilsenbeck S.G., Subler M.A., Windle J.J. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Molecular and Cellular Biology 1997, 17:723-731.
76. Koboldt D.C., Fulton R.S., McLellan M.D., Schmidt H., Kalicki-Veizer J., McMichael J.F., et al. Comprehensive molecular portraits of human breast tumors. Nature 2012, 490:61-70.
77. Koenders P.G., Beex L.V., Kienhuis C.B., Kloppenborg P.W., Benraad T.J. Epidermal growth factor receptor and prognosis in human breast cancer: A prospective study. Breast Cancer Research and Treatment 1993, 25:21-27.
78. Korpelainen E.I., Karkkainen M.J., Tenhunen A., Lakso M., Rauvala H., Vierula M., et al. Overexpression of VEGF in testis and epididymis causes infertility in transgenic mice: Evidence for nonendothelial targets for VEGF. The Journal of Cell Biology 1998, 143:1705-1712.
79. Kuperwasser C., Hurlbut G.D., Kittrell F.S., Dickinson E.S., Laucirica R., Medina D., et al. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. The American Journal of Pathology 2000, 157:2151-2159.
80. Kwan H., Pecenka V., Tsukamoto A., Parslow T.G., Guzman R., Lin T.P., et al. Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Molecular and Cellular Biology 1992, 12:147-154.
81. Lachman L.B., Rao X.M., Kremer R.H., Ozpolat B., Kiriakova G., Price J.E. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Therapy 2001, 8:259-268.
82. Lakshminarayanan V., Thompson P., Wolfert M.A., Buskas T., Bradley J.M., Pathangey L.B., et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:261-266.
83. Lammie G.A., Peters G. Chromosome 11q13 abnormalities in human cancer. Cancer Cells 1991, 3:413-420.
84. Lane T.F., Leder P. Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene 1997, 15:2133-2144.
85. Lanza-Jacoby S., Miller S., Flynn J., Gallatig K., Daskalakis C., Masferrer J.L., et al. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiology, Biomarkers & Prevention 2003, 12:1486-1491.
86. Lewandoski M. Conditional control of gene expression in the mouse. Nature Reviews. Genetics 2001, 2:743-755.
87. Li Y., Hively W.P., Varmus H.E. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 2000, 19:1002-1009.
88. Li M., Hu J., Heermeier K., Hennighausen L., Furth P.A. Expression of a viral oncoprotein during mammary gland development alters cell fate and function: Induction of p53-independent apoptosis is followed by impaired milk protein production in surviving cells. Cell Growth & Differentiation 1996, 7(1):3-11.
89. Li M., Hu J., Heermeier K., Hennighausen L., Furth P.A. Apoptosis and remodeling of mammary gland tissue during involution proceeds through p53-independent pathways. Cell Growth & Differentiation: The molecular biology journal of the American Association for Cancer Research 1996, 7(1):13-20.
90. Li M., Lewis B., Capuco A.V., Laucirica R., Furth P.A. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis. Oncogene 2000, 19:1010-1019.
91. Li B., Murphy K.L., Laucirica R., Kittrell F., Medina D., Rosen J.M. A transgenic mouse model for mammary carcinogenesis. Oncogene 1998, 16:997-1007.
92. Liao D.J., Dickson R.B. c-Myc in breast cancer. Endocrine-related Cancer 2000, 7:143-164.
93. Lin D.I., Lessie M.D., Gladden A.B., Bassing C.H., Wagner K.U., Diehl J.A. Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene 2008, 27:1231-1242.
94. Liu C.Y., Flesken-Nikitin A., Li S., Zeng Y., Lee W.H. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes & Development 1996, 10:1835-1843.
95. Lu C., Speers C., Zhang Y., Xu X., Hill J., Steinbis E., et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. Journal of the National Cancer Institute 2003, 95(24):1825-1833.
96. Malkin D. Li-fraumeni syndrome. Genes & Cancer 2011, 2:475-484.
97. Maroulakou I.G., Anver M., Garrett L., Green J.E. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:11236-11240.
98. Marozkina N.V., Stiefel S.M., Frierson H.F., Parsons S.J. MMTV-EGF receptor transgene promotes preneoplastic conversion of multiple steroid hormone-responsive tissues. Journal of Cellular Biochemistry 2008, 103:2010-2018.
99. Marquis S.T., Rajan J.V., Wynshaw-Boris A., Xu J., Yin G.Y., Abel K.J., et al. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nature Genetics 1995, 11:17-26.
100. Matsui Y., Halter S.A., Holt J.T., Hogan B.L., Coffey R.J. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 1990, 61:1147-1155.
101. Mes A.M., Hassell J.A. Polyoma viral middle T-antigen is required for transformation. Journal of Virology 1982, 42:621-629.
102. Moller P., Mechtersheimer G., Kaufmann M., Moldenhauer G., Momburg F., Mattfeldt T., et al. Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast. Virchows Archiv. A, Pathological Anatomy and Histopathology 1989, 414:157-164.
103. Moody S.E., Sarkisian C.J., Hahn K.T., Gunther E.J., Pickup S., Dugan K.D., et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002, 2:451-461.
104. Muller W.J., Sinn E., Pattengale P.K., Wallace R., Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54:105-115.
105. Muller P.A.J., Vousden K.H. p53 mutations in cancer. Nature Cell Biology 2013, 15:2-8.
106. Muthuswamy S.K., Siegel P.M., Dankort D.L., Webster M.A., Muller W.J. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Molecular and Cellular Biology 1994, 14:735-743.
107. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10(6):515-527.
108. Nguyen D.X., Bos P.D., Massague J. Metastasis: From dissemination to organ-specific colonization. Nature Reviews. Cancer 2009, 9:274-284.
109. Obermair A., Kucera E., Mayerhofer K., Speiser P., Seifert M., Czerwenka K., et al. Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival. International Journal of Cancer 1997, 74:455-458.
110. Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harbor Perspectives in Biology 2010, 2:a001008.
111. Ottewell P.D., Coleman R.E., Holen I. From genetic abnormality to metastases: Murine models of breast cancer and their use in the development of anticancer therapies. Breast Cancer Research and Treatment 2006, 96:101-113.
112. Palmiter R.D., Sandgren E.P., Koeller D.M., Brinster R.L. Distal regulatory elements from the mouse metallothionein locus stimulate gene expression in transgenic mice. Molecular and Cellular Biology 1993, 13:5266-5275.
113. Advanced protocols for animal transgenesis. An ISTT manual 2011, S. Pease, T.L. Saunders (Eds.).
114. Petitjean A., Achatz M.I., Borresen-Dale A.L., Hainaut P., Olivier M. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26(15):2157-2165.
115. Ray D., Terao Y., Christov K., Kaldis P., Kiyokawa H. Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis. Neoplasia 2011, 13:439-444.
116. Ray D., Terao Y., Nimbalkar D., Hirai H., Osmundson E.C., Zou X., et al. Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Research 2007, 67:6605-6611.
117. Ren S., Cai H.R., Li M., Furth P.A. Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 2002, 21:4335-4339.
118. Robinson G.W. Cooperation of signalling pathways in embryonic mammary gland development. Nature Reviews. Genetics 2007, 8:963-972.
119. Russo J., Moral R., Balogh G.A., Mailo D., Russo I.H. The protective role of pregnancy in breast cancer. Breast Cancer Research 2005, 7:131-142.
120. Russo J., Russo I.H. Development of the human breast. Maturitas 2004, 49:2-15.
121. Sandgren E.P., Schroeder J.A., Qui T.H., Palmiter R.D., Brinster R.L., Lee D.C. Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Research 1995, 55:3915-3927.
122. Santarelli R., Tzeng Y.J., Zimmermann C., Guhl E., Graessmann A. SV40 T-antigen induces breast cancer formation with a high efficiency in lactating and virgin WAP-SV-T transgenic animals but with a low efficiency in ovariectomized animals. Oncogene 1996, 12:495-505.
123. Saunders T.L. Inducible transgenic mouse models. Methods in Molecular Biology 2011, 693:103-115.
124. Schoeffner D.J., Matheny S.L., Akahane T., Factor V., Berry A., Merlino G., et al. VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Laboratory Investigation; a journal of technical methods and pathology 2005, 85:608-623.
125. Schoenenberger C.A., Andres A.C., Groner B., van der Valk M., LeMeur M., Gerlinger P. Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. The EMBO Journal 1988, 7:169-175.
126. Schoenherr R.M., Kelly-Spratt K.S., Lin C., Whiteaker J.R., Liu T., Holzman T., et al. Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer. Proteomics. Clinical Applications 2011, 5:179-188.
127. Schondorf T., Andrack A., Niederacher D., Scharl A., Becker M., Engel H., et al. H-ras gene amplification or mutation is not common in human primary breast cancer. Oncology Reports 1999, 6:1029-1033.
128. Schreiber A.B., Winkler M.E., Derynck R. Transforming growth factor-alpha: A more potent angiogenic mediator than epidermal growth factor. Science 1986, 232:1250-1253.
129. Shibata M.A., Liu M.L., Knudson M.C., Shibata E., Yoshidome K., Bandey T., et al. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: Reduction in protective apoptotic response at the preneoplastic stage. The EMBO Journal 1999, 18:2692-2701.
130. Shibata M.A., Maroulakou I.G., Jorcyk C.L., Gold L.G., Ward J.M., Green J.E. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: Suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Research 1996, 56:2998-3003.
131. Sicinski P., Donaher J.L., Parker S.B., Li T., Fazeli A., Gardner H., et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995, 82:621-630.
132. Siegel P.M., Dankort D.L., Hardy W.R., Muller W.J. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Molecular and Cellular Biology 1994, 14:7068-7077.
133. Siegel P.M., Ryan E.D., Cardiff R.D., Muller W.J. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer. The EMBO Journal 1999, 18:2149-2164.
134. Sinn E., Muller W., Pattengale P., Tepler I., Wallace R., Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 1987, 49:465-475.
135. Slamon D.J., deKernion J.B., Verma I.M., Cline M.J. Expression of cellular oncogenes in human malignancies. Science 1984, 224:256-262.
136. Spandidos D.A. Oncogene activation in malignant transformation: A study of H-ras in human breast cancer. Anticancer Research 1987, 7:991-996.
137. Spandidos D.A., Field J.K., Agnantis N.J., Evan G.I., Moore J.P. High levels of c-myc protein in human breast tumours determined by a sensitive ELISA technique. Anticancer Research 1989, 9:821-826.
138. Stewart T.A., Pattengale P.K., Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984, 38:627-637.
139. Sukumar S., McKenzie K., Chen Y. Animal models for breast cancer. Mutation Research 1995, 333:37-44.
140. Taneja P., Frazier D.P., Kendig R.D., Maglic D., Sugiyama T., Kai F., et al. MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Review of Molecular Diagnostics 2009, 9:423-440.
141. Tremblay P.J., Pothier F., Hoang T., Tremblay G., Brownstein S., Liszauer A., et al. Transgenic mice carrying the mouse mammary tumor virus ras fusion gene: Distinct effects in various tissues. Molecular and Cellular Biology 1989, 9:854-859.
142. Tsukamoto A.S., Grosschedl R., Guzman R.C., Parslow T., Varmus H.E. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988, 55:619-625.
143. Tzeng Y.J., Gottlob K., Santarelli R., Graessmann A. The SV40T-antigen induces premature apoptotic mammary gland involution during late pregnancy in transgenic mice. FEBS Letters 1996, 380:215-218.
144. Tzeng Y.J., Guhl E., Graessmann M., Graessmann A. Breast cancer formation in transgenic animals induced by the whey acidic protein SV40 T antigen (WAP-SV-T) hybrid gene. Oncogene 1993, 8:1965-1971.
145. Ullrich R.L., Bowles N.D., Satterfield L.C., Davis C.M. Strain-dependent susceptibility to radiation-induced mammary cancer is a result of differences in epithelial cell sensitivity to transformation. Radiation Research 1996, 146:353-355.
146. Ursini-Siegel J., Schade B., Cardiff R.D., Muller W.J. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nature Reviews. Cancer 2007, 7:389-397.
147. Vargo-Gogola T., Rosen J.M. Modelling breast cancer: One size does not fit all. Nature Reviews. Cancer 2007, 7:659-672.
148. Voncken J.W. Genetic modification of the mouse: General technology - pronuclear and blastocyst injection. Methods in Molecular Biology 2011, 693:11-36.
149. Wagner K.U., McAllister K., Ward T., Davis B., Wiseman R., Hennignausen L. Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Research 2001, 10:545-553.
150. Wang T.C., Cardiff R.D., Zukerberg L., Lees E., Arnold A., Schmidt E.V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994, 369:669-671.
151. Wang C., Schwab L.P., Fan M., Seagroves T.N., Buolamwini J.K. Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer. Cancer Prevention Research (Phila) 2013, 6:437-447.
152. Watson C.J., Khaled W.T. Mammary development in the embryo and adult: A journey of morphogenesis and commitment. Development 2008, 135:995-1003.
153. Weaver Z., Montagna C., Xu X., Howard T., Gadina M., Brodie S.G., et al. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 2002, 21:5097-5107.
154. Webster J., Wallace R.M., Clark A.J., Whitelaw C.B. Tissue-specific, temporally regulated expression mediated by the proximal ovine beta-lactoglobulin promoter in transgenic mice. Cellular & Molecular Biology Research 1995, 41:11-15.
155. Wen J., Kawamata Y., Tojo H., Tanaka S., Tachi C. Expression of whey acidic protein (WAP) genes in tissues other than the mammary gland in normal and transgenic mice expressing mWAP/hGH fusion gene. Molecular and Reproductive Development 1995, 41:399-406.
156. Wiesen J.F., Young P., Werb Z., Cunha G.R. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development 1999, 126:335-344.
157. Wyckoff J.B., Wang Y., Lin E.Y., Li J.F., Goswami S., Stanley E.R., et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Research 2007, 67:2649-2656.
158. Wyckoff J., Wang W., Lin E.Y., Wang Y., Pixley F., Stanley E.R., et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Research 2004, 64:7022-7029.
159. Xu X., Wagner K.U., Larson D., Weaver Z., Li C., Ried T., et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genetics 1999, 22:37-43.
160. Yoshidome K., Shibata M.A., Couldrey C., Korach K.S., Green J.E. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: Paradoxical loss of estrogen receptoralpha expression during tumor progression. Cancer Research 2000, 60:6901-6910.
161. Yoshiji H., Gomez D.E., Shibuya M., Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Research 1996, 56:2013-2016.
162. Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411:1017-1021.
163. Yu Q., Sicinska E., Geng Y., Ahnstrom M., Zagozdzon A., Kong Y., et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006, 9:23-32.
164. Zagozdzon A.M., O'Leary P., Callanan J.J., Crown J., Gallagher W.M., Zagozdzon R. Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice. BMC Cancer 2012, 12:209.
165. Zhang M., Shi Y., Magit D., Furth P.A., Sager R. Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice. Oncogene 2000, 19:6053-6058.